C4 Therapeutics Company Profile: CCCC Business, Executives & Facts

Key StatisticsCurrency:USD

EPS(TTM)

-1.52

P/E(TTM)

-1.41

BVPS

3.06

P/B

0.69

Revenue(2024 Q4)

5.18M

YoY

58.75%

Net Income(2024 Q4)

-34.57M

YoY

0.52%

Gross Margin(TTM)

100.00%

Net Margin(TTM)

-295.96%

ROE(TTM)

-45.58%

Debt ratio

38.22%

Dividend Yield(TTM)

--

Payout Ratio

--

Profile

C4 Therapeutics, Inc.

 A developer of novel therapies for cancer and other diseases using its proprietary Cell Selection and Engineering (CSE) platform 

C4 Therapeutics, Inc., was incorporated in Delaware on October 7, 2015. The company is a biopharmaceutical company dedicated to harnessing the body's natural regulation of protein levels to develop new therapeutic drug candidates to target and destroy disease-causing proteins to treat cancer, neurodegenerative diseases and other diseases.

Related Sections

Biotechnology+1.37%

Pharma Tracker

No Upcoming Event

Stay ahead with our Pharma Tracker: Monitor the latest developments in new drug research, financial health, and FDA updates for the company

Revenue BreakdownCurrency:USD

Data source:2024 FY

Total

35.58M

Name

Revenue

Proportion

MKDG Agreement

7.30M

20.53%

MERCK Agreement

3.98M

11.18%

Betta Agreements

3.42M

9.60%

Roche Agreement

3.99M

11.21%

Biogen License Agreement

16.90M

47.49%

Major shareholders

Marc A. Cohen;Alain J. Cohen

Perceptive Advisors

Bihua Chen

DividendsCurrency:USD

No Data

Net Income Attributable to Parent

Total Cash Dividends

Payout Ratio

Institutional Holdings

Totally

108

institutions reported their ownerships on

CCCC

Institutional Holding Ratio

Price

Insider Transactions

Net increase

Net decrease

Price

Stock split and consolidation

Executive Profile

Feedback

Disclaimer: All data and information presented above are from third-party data sources. They are for reference only and do not constitute any investment advice.

Market Data Risk Disclosure|Privacy Policy